Investors & Media
Corporate Profile
ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy™ (ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type 1 allergic reactions; including food, medications and insect bites that could lead to life-threatening anaphylaxis.
NEWS & RELEASES
UPCOMING & RECENT EVENTS
There are currently no events to display
Media Relations:
Caroline Cunningham
Caroline.Cunningham@porternovelli.com
Investor Contact:
Justin Chakma
justinc@richardl77.sg-host.com